Shots:
- Frontier has entered into an exclusive licensing agreement with GSK for two Small Interfering RNA (siRNA) assets in immunology, incl. one IND-stage candidate & one preclinical program
- As per the deal, GSK will gain exclusive global rights to develop, manufacture, & commercialize two of Frontier’s siRNA candidates, while Frontier will receive $40M upfront, up to ~$963M in development, regulatory, & commercial milestones, plus tiered royalties on net sales
- Frontier will advance the 2 assets initially, conducting a P-I trial in China for one & completing IND-enabling studies for the other, after which GSK will lead global clinical development, regulatory filings, & commercialization
Ref: PRnewswire | Image: GSK & Frontier | Press Release
Related News: GSK Reports the EC Approval of Exdensur (Depemokimab) for Asthma with Type 2 Inflammation and CRSwNP
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
